Search

Displaying results 2101 - 2110 of 8517 in total
  1. Drug

    Denosumab

    go.drugbank.com/drugs/DB06643
    ApprovedInvestigational

    [A263066] An Denosumab biosimilar, Jubbonti, was approved for Health Canada in February 2024.[L52083]. … [A263066] Denosumab was approved by the FDA approved on June 2010 for the treatment of osteoporosis in postmenopausal women.

  2. Drug

    Ulobetasol

    go.drugbank.com/drugs/DB00596
    Approved

    [L15047,L15052,L15102] Ulobetasol was granted FDA approval on 17 December 1990.[L15047]

  3. Drug

    Solriamfetol

    go.drugbank.com/drugs/DB14754
    ApprovedInvestigational

    Solriamfetol was given FDA approval in 2019[FDA Label].

  4. Drug

    Zolmitriptan

    go.drugbank.com/drugs/DB00315
    ApprovedInvestigational

    [A462, L12978] [Sumatriptan] was the first triptan to be developed, but had poor oral bioavailability and lipophilicity. … [A193797] Zolmitriptan was first approved by the FDA for sale by Zeneca Pharmaceuticals under the trade name Zomig® on November 25, 1997.

  5. Drug

    Fenofibrate

    go.drugbank.com/drugs/DB01039
    ApprovedInvestigational

    [L8588,L8591] Fenofibrate was granted FDA approval on 31 December 1993.[L8585]

  6. Drug

    Obiltoxaximab

    go.drugbank.com/drugs/DB05336
    Approved

    It has an approximate molecular weight of 148 kDa.

  7. Drug

    Lyme disease vaccine (recombinant OspA)

    go.drugbank.com/drugs/DB00045
    ApprovedWithdrawn

    It is conjugated with alum (aluminum hydroxide) as an adjuvant. … Vaccine against Lyme disease that contains lipoprotein OspA, an outer surface protein of Borrelia burgdorferi sensu stricto ZS7, as expressed by Escherichia coli.

  8. Drug

    Ripasudil

    go.drugbank.com/drugs/DB13165
    Investigational

    It was first approved for treatment in Japan in September 2014. This medication is available in the form of a 0.4% eye drop solution under the brand name Glanatec. … Ripasudil, as hydrochloride hydrate (K-115), is a specifc Rho-associated coiled-coil containing protein kinase (ROCK) inhibitor used for the treatment of glaucoma and ocular hypertension.

  9. Drug

    Ticagrelor

    go.drugbank.com/drugs/DB08816
    ApprovedInvestigational

    [A2903] It is marketed by Astra Zeneca as Brilinta in the US[L14201] and Brilique or Possia in the EU,[L14207]. Ticagrelor was granted EMA approval on 3 December 2010. … [L14207] Ticagrelor was granted FDA approval on 20 July 2011.[L14201]

  10. Drug

    BMS-488043

    go.drugbank.com/drugs/DB05532
    Experimental

    BMS-488043 has been investigated as an anti-HIV agent.